GLA and Fabry disease: In the BRIGHT trial, a phase 3, open label, switch over study to assess safety, efficacy and pharmacokinetics of pegunigalsidase alfa 2 mg/kg (Bodyweight) has been administered every 4 weeks for 52 weeks in Fabry disease patients previously treated with ERT (Fabrazyme® (Agalsidase beta) or Replagal® (Agalsidase alfa)) for at least 3 years.